Her3-Targeted Immunotherapy Pipeline Review
Her3-Targeted Immunotherapy Pipeline Review
Target: Her3; human epidermal growth factor receptor 3; ErbB3
Product Category: Antibody;
This product provides basic information on immunotherapeutics in R&D targeting Her3.
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
- Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for immunotherapeutics targeting Her3 (prerequisite: access to internet).
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
HER3 is a member of the epidermal growth factor receptor (ERBB) family of tyrosine kinase receptors. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation.
Her3 is overexpressed in a broad range of tumors and is associated with disease progression and poor survival. For example, more than 50% of melanoma, cervical, lung, gastric, colorectal, and ovarian cancers show overexpression of HER3, while in breast, pancreatic and prostate cancers the overexpression ranges between 25-40%. In addition, recent studies show that HER3 expression is significantly induced in tumors during metastasis (in colorectal) and during acquired resistance to tyrosine kinase inhibitors (TKI) in lung cancers.
This widespread overexpression of HER3 makes it an ideal target for antibody drug conjugates (ADCs) and bispecific antibodies targeting Her3 and a second, co-expressed tumor associated antigen. In addition, these new drug modalities promise improved antitumor activity compared to first generation naked antibodies.